Drugs

Article	Citations
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	490
Teclistamab: First Approval	465
Senaparib: First Approval	276
Targeting DNA Damage Response Deficiency in Thoracic Cancers	247
Spesolimab for the Treatment of Generalized Pustular Psoriasis	242
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	219
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	191
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	165
Eftrenonacog Alfa: A Review in Haemophilia B	161
Acknowledgement to Referees	155
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	146
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	143
Epcoritamab: First Approval	140
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	138
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	138
Vorasidenib: First Approval	124
New Therapies on the Horizon for Primary Biliary Cholangitis	123
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	122
Aprocitentan: First Approval	109
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	103
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	102
Repotrectinib: First Approval	100
Ivarmacitinib Sulfate: First Approval	99
Acoltremon: First Approval	98
Cosibelimab: First Approval	92

Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	91
Olipudase Alfa: First Approval	89
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	88
Danicopan: First Approval	87
Tolebrutinib: First Approval	86
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	84
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	83
Drugs in Development to Manage Acute Pain	81
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	80
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	79
Lenacapavir: First Approval	77
Efficacy and Harms of Opioid Analgesics for Acute Pain: Overview of Systematic Reviews and Meta-analyses	77
Androgenetic Alopecia: Therapy Update	75
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	75
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	72
Cancer Pain Treatment Strategies in Patients with Cancer	68
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	67
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	65
Sibeprenlimab: First Approval	65
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	64
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	64
Mosunetuzumab: First Approval	64
Mazdutide: First Approval	63
Taletrectinib: First Approval	63
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	63
Tovorafenib: First Approval	62
Pozelimab: First Approval	60
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	58
Correction to: Tapinarof Cream 1%: First Approval	58
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	57
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	57
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	56
Targeting Inflammation in Bronchiectasis	56
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	56
Managing Burning Mouth Syndrome: Current and Future Directions	54
Ifupinostat: First Approval	53
Dorzagliatin: First Approval	53
Sunvozertinib: First Approval	53
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	53
Correction to: Prevention and Treatment of Monkeypox	53
Pixavir Marboxil: First Approval	51
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	48
The Place of Cannabinoids in the Treatment of Gynecological Pain	47
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	47
Correction to: Concizumab: First Approval	47
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	46
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	46
Birch Bark Extract: A Review in Epidermolysis Bullosa	44
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	44
Ozoralizumab: First Approval	43

Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	42
Gepirone Extended-Release: First Approval	42
Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies	42
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	41
Correction to: Remdesivir: A Review in COVID-19	41
Catumaxomab: First Approval	41
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	40
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	40
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	40
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades	40
Givinostat: First Approval	39
Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review	39
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	39
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	39
Tirzepatide: A Review in Type 2 Diabetes	39
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	39
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	39
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	39
Correction: Ifupinostat: First Approval	38
Ensitrelvir Fumaric Acid: First Approval	38
Atrasentan: First Approval	38
Correction: Teprotumumab: A Review in Thyroid Eye Disease	38
Sequential Use of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients with Breast Cancer: A Pharmacological Approach to Support the Clinical Rationale	38
Fezolinetant: First Approval	37
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	37
Becotatug Vedotin: First Approval	36
Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects	36
Antifungal Treatment Regimens as Primary Therapy for Invasive Aspergillosis: A Systematic Review and Network Meta-analysis	35
Eye Involvement and Management in Inherited Epidermolysis Bullosa	35
Avacincaptad Pegol: First Approval	35
Futibatinib: First Approval	35
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	35
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	34
Correction: Iptacopan: First Approval	34
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review	34
Zeprumetostat: First Approval	33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	33
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	33
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	33
Beremagene Geperpavec: First Approval	33
Managing Pain in Fibromyalgia: Current and Future Options	33
Imetelstat: First Approval	32
Zastaprazan: First Approval	32
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	32
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	32
Lotilaner Ophthalmic Solution 0.25%: First Approval	32
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	31
Acknowledgement to Referees	31
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	31
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	30
Mavorixafor: First Approval	30
Diagnosis and Treatment of AL Amyloidosis	29
Retifanlimab: First Approval	29
Nogapendekin alfa Inbakicept: First Approval	29
Sepiapterin: First Approval	29
Revumenib: First Approval	29
Crinecerfont: First Approval	29
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	29
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	28
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	28
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	28
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	28
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Antibacterials with Novel Chemical Scaffolds in Clinical Development	27
Correction to: Sparsentan: First Approval	27
Zolbetuximab: First Approval	27
Methadone for Cancer Pain Management in Children: A Review of Literature	27
Onradivir: First Approval	27
Correction: Zastaprazan: First Approval	27
Remdesivir: A Review in COVID-19	27
Correction to: Spesolimab: First Approval	27
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	27
Tradipitant: First Approval	27
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	26
Ravulizumab: A Review in Generalised Myasthenia Gravis	26
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	26
Keverprazan Hydrochloride: First Approval	26
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	26

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy	25
Marstacimab: First Approval	25
Publisher Correction: Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clos	25
Elranatamab: First Approval	25
Novel Drug Therapeutics in Celiac Disease: A Pipeline Review	25
Spesolimab: First Approval	24
Current and Future Pharmacological Interventions for Acquired Hypothalamic Obesity	24
Refractory Systemic Lupus Erythematosus: Identification and Pharmacological Management	24
A Review of RRx-001: A Late-Stage Multi-Indication Inhibitor of NLRP3 Activation and Chronic Inflammation	24
Lecanemab: First Approval	24
Nadofaragene Firadenovec: First Approval	24
Treatment of Osteoporosis and Osteoarthritis in the Oldest Old	24
Tixagevimab + Cilgavimab: First Approval	24
Correction to: Rozanolixizumab: First Approval	23
Ritlecitinib: First Approval	23
Ziftomenib: First Approval	23
Zongertinib: First Approval	23
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions	23
Correction to: Mavacamten: First Approval	23
Amubarvimab/Romlusevimab: First Approval	23
Comment on: ‘Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know?’	22
Tofersen: First Approval	22
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study	22
Pucotenlimab: First Approval	22
Targeted Small Molecules for Systemic Lupus Erythematosus: Drugs in the Pipeline	22
Comment on “Trientine Tetrahydrochloride, From Bench to Bedside: A Narrative Review”	22
Paltusotine: First Approval	22
Correction to: Ozanimod: A Review in Ulcerative Colitis	21
Benefits and Liabilities of Benzodiazepines and Z-Drugs: What We Know and What We Don’t Know	21
Pharmacological Therapies in Paroxysmal Nocturnal Haemoglobinuria: Focus on Complement Inhibition	21
Elafibranor: First Approval	21
New Developments in Glucagon Treatment for Hypoglycemia	21
Trastuzumab Rezetecan: First Approval	20
Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis	20
Association of Glucagon-Like Peptide-1 Receptor Agonist with Progression to Liver Cirrhosis and Alcohol-Related Admissions in Patients with Alcohol Use Disorder and Diabetes: A Retrospective Cohort St	20
Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments	20
Gepotidacin: First Approval	20
Valoctocogene Roxaparvovec: First Approval	20
Talquetamab: First Approval	20
Correction: Senaparib: First Approval	20
Differentiating IL-23 Inhibitors in Crohn’s Disease	20
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders	20
Eplontersen: First Approval	20
A Meta-analysis Exploring the Efficacy of Neuropathic Pain Medication for Low Back Pain or Spine-Related Leg Pain: Is Efficacy Dependent on the Presence of Neuropathic Pain?	20
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections	19
Tirzepatide: First Approval	19
TKI Treatment Sequencing in Advanced Gastrointestinal Stromal Tumors	19
Sipavibart: First Approval	19
PI3K Inhibitors as Potential Therapeutic Agents for the Treatment of COPD with Associated Atherosclerosis	19
Minimal Residual Disease Negativity as the Primary Goal of Multiple Myeloma Therapy	18
PCSK9 Inhibitors: A Potential Priority Choice for Lipid Management in Patients with Diabetic Kidney Disease	18
Mirvetuximab Soravtansine: First Approval	18
Ensifentrine Plus a Long-Acting Muscarinic Antagonist in COPD: A Trifunctional Dual Bronchodilation Perspective	18
Iptacopan: First Approval	18
Dimdazenil: First Approval	18
Tunlametinib: First Approval	18
Motixafortide: First Approval	18
20-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults	18
Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies	18
Pharmacological, Natural and Emerging Therapies for Meibomian Gland Dysfunction: A Review	18
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder	18
Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis	17
Treatment Options in Spinal Muscular Atrophy: A Pragmatic Approach for Clinicians	17
Sulbactam/Durlobactam: First Approval	17
Nemolizumab: First Approval	17
Vimseltinib: First Approval	17
Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials	17
Drugs in Development to Treat IgA Nephropathy	17
Linzagolix: First Approval	17
Cabotegravir Extended-Release Injectable Suspension: A Review in HIV-1 Pre-Exposure Prophylaxis	17
Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action	17
Use of Levosimendan in Patients with Pulmonary Hypertension: What is the Current Evidence?	17
Biased Kappa-opioid Agonist Strategies in Pain Management: Approaches to Clinical Benefits with Reduced Adverse Effects	17
Clesrovimab: First Approval	17
Drug-Induced Pigmentation: A Review	17
Vamorolone: First Approval	17
Results from Expanded Access Programs: A Review of Academic Literature	17
Tegileridine: First Approval	17
Chinese Herbal Medicines for Coronary Heart Disease: Clinical Evidence, Pharmacological Mechanisms, and the Interaction with Gut Microbiota	17
Postpartum Depression: A Clinical Review of Impact and Current Treatment Solutions	17
Fitusiran: First Approval	16
Ebronucimab: First Approval	16
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis	16
Systemic Therapy for Advanced Thyroid Cancer—New Personalized Options	16
Rezvilutamide: First Approval	16
Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside	16
In Search of the Optimal Antithrombotic Regimen for Intracerebral Hemorrhage Survivors with Atrial Fibrillation	16
Weight Loss Versus Glycemic Control as the Primary Treatment Target in Newly Diagnosed Type 2 Diabetes: Why Choose When You Can Have Both?	16
Extended and Continuous Infusion of Novel Protected β-Lactam Antibiotics: A Narrative Review	15
Oteseconazole: First Approval	15
Managing Psoriatic Arthritis Patients Presenting with Axial Symptoms	15
Famitinib: First Approval	15
Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	15
Pirtobrutinib: First Approval	15
Vonoprazan: A Review in Helicobacter pylori Infection	15